Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Esophageal Neoplasms: early-phase trial registry
6 of 13 indexed Esophageal Neoplasms trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 6 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Esophageal Neoplasms: 13 US clinical trials tracked, 6 recruiting.
Esophageal Neoplasms is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Merck Sharp & Dohme, running 3 of these trials.
Enrollment posture brief
Registry condition esophageal-neoplasms
OPEN 6 | RECR 46% | LATE 1 | EARLY 8 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: B-cell Lymphoma (46% recruiting · 39 trials)
Esophageal Neoplasms lists 6 open slots (46% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Esophageal Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Esophageal Neoplasms recruits in line with its size-band peers.
6 of 13 indexed trials (46.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Esophageal Neoplasms research.
Merck Sharp & Dohme accounts for 3 of 13 trials (23.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Esophageal Neoplasms enrolment sits around 160 participants.
Median target enrolment is 160 among the 13 trials that report a genuine target (sentinel values excluded). 4 of those (30.8%) plan for fewer than 100 participants.
-
Esophageal Neoplasms research is mostly interventional.
10 interventional and 3 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
Universitaire Ziekenhuizen KU Leuven
NCT04654975
Distribution of Lymph Node Metastases in Esophageal Carcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
NCT03222895
Mayo Clinic Upper Digestive Disease Survey
Mayo Clinic
NCT02530983
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07213791
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Merck Sharp & Dohme
NCT06445972
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Merck Sharp & Dohme
NCT06469944
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
Merck Sharp & Dohme
NCT03189719
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Leap Therapeutics
NCT02013154
Removal of the Evolution® Esophageal Stent - Fully Covered
Cook Group Incorporated
NCT01900691
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Washington University School of Medicine
NCT01928290
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Duke University
NCT00447330
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT00390416
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
Dartmouth-Hitchcock Medical Center
NCT00153881
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Esophageal Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Esophageal Neoplasms trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Esophageal Neoplasms page
13 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Esophageal Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Merck Sharp & Dohme sponsors the most Esophageal Neoplasms trials on record, review their full trial history before evaluating a specific study. See Merck Sharp & Dohme's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Esophageal Neoplasms condition card totals 13 registered trials; most-linked intervention Paclitaxel; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.